Storage | Store at 4°C |
Description | PD-1 (programmed cell death protein 1), also known as CD279, is a membrane protein of the human immunoglobulin superfamily, expressed on the surface of T cells, primary B cells, and myeloid-derived dendritic cells. Its ligand, called PD-L1 (also known as CD274), is a type 1 transmembrane protein mainly expressed on the cell surface of tumor cells or antigen-presenting cells. PD-1 and PD-L1 were also found to be co-expressed on the surface of SCLC cancer cells. PD-1/PD-L1 act as inhibitory checkpoint molecules in the immune system. PD-1 binds to PD-L1 to form a complex and transmit inhibitory signals to reduce the proliferation and activity of killer T lymphocytes. Blocking PD-1 with anti-PD-1 antibody, or blocking PD-L1 with anti-PD-L1 antibody, can inhibit the formation of PD-1/PD-L1 complex, thereby activating the immune system to attack tumors. Therefore, both anti-PD-1 and anti-PD-L1 antibodies have been used as adjuvant therapy for certain types of cancer. This product is designed as a tool for the delivery and expression of anti-PD-1 scFv(Nivolumab)-mutant Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-PD-1 scFv(Nivolumab)-mutant Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. This anti-PD-1 scFv(Nivolumab)-mutant Fc protein is a secreted protein, approximately 75 kD |
Lipid composition | SM-102/DSPC/Cholesterol/DMG-PEG2000 |
Technical Notes | Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex. mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended |
Encoding mRNA | PD-1 scFv (Nivolumab)-mutant Fc |
In Vitro QC (Cell Types) | HEK293S |
Technology Applications | Antibody research |
Required fields are marked with *
×Product Name | Catalog | Lipid composition | Liposome Size | Price |
---|---|---|---|---|
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDL23-081-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDL23-082-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1695 | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDPM12 | SM-102/DSPC/cholesterol/DMG-PEG2000 | INQUIRY | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDL23-038-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDPM04 | SM-102/DSPC/cholesterol/DMG-PEG2000 | INQUIRY | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDL23-085-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDL23-092-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1695 | |
Clipos™ PD-1 scFv (Nivolumab)-mutant Fc mRNA Lipid Nanoparticles | CDPM03 | INQUIRY |
1. Download the template.
2. Enter product information on the template (maximum number of products: 200).
3. Load the file using selector below.
1. Download the template.
2. Enter product information on the template (maximum number of products: 200).
3. Load the file using selector below.